VALANX Biotech announces promising results in first in-vivo study of novel protein conjugate therapy
Study demonstrates pre-clinical efficacy of lead program VLX101 in treating autoimmune disease
DefiniGEN and Atelerix collaborate to ship in vitro cell models internationally without the need for freezing or cryopreservation
Cambridge and Newcastle UK: DefiniGEN Ltd., and Atelerix Ltd., announces they have successfully shipped in vitro liver models from the UK to a top tier pharma customer in the US.
H.E.L Group extends sales and support with appointment of specialist distributors
Distributors will provide added application specific support for H.E.L’s biotechnology and chemical synthesis product portfolios in the USA, Spain and Portugal.
Cellular Origins and Cell and Gene Therapy Catapult collaborate to demonstrate universal automation of CGT manufacturing
Partnership to develop and implement Cellular Origins’ robotic platform Constellation for universal automation of CGT manufacturing at CGT Catapult’s Stevenage Manufacturing Innovation Centre
Secarna Pharmaceuticals and Orbit Discovery enter collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide therapeutics
Partnership expands spectrum of Secarna’s capabilities for the development of targeted ASOs beyond antibodies and sugar molecules
Exonate appoints Dr Rafiq Hasan as Non-Executive Director
Appointment brings extensive experience in global pharma leadership and progressing ophthalmology drugs to market and further strengthens Board
Closed Loop Medicine appoints Paul Johnson as Non-Executive Director
Appointment of digital healthcare leader to Board to support the Company as it enters next phase of commercial development
ERS Genomics and IRBM sign CRISPR/Cas9 license agreement
License agreement provides IRBM access to CRISPR gene editing technology to be applied across its drug discovery services offering
Closed Loop Medicine and Pharmanovia commence OptiZest study for their first precision medicine combination therapeutic
Proof-of-Concept study to investigate personalized dose management of first-line anti-hypertensive in improving blood pressure control remotel
Enhanc3D Genomics appoints Hazel Jones as Chief Executive Officer
Cambridge, UK: Enhanc3D Genomics, a company developing disruptive technologies to unlock the 3D genome for use in novel target identific
PlaqueTec and the Babraham Institute collaborate on early phase target discovery and development
Campus Innovation Award (CIA)-funded project evaluated lead compounds predicted to bind a pro-inflammatory protein discovered by PlaqueTec
ArgusEye closes €2.8 million funding to accelerate bioprocessing
Led by Voima Ventures and co-led by existing investor Eir Ventures
ERS Genomics appoints John E Milad as Chief Executive Officer
Dublin, Ireland: ERS Genomics Limited (‘ERS’), the CRISPR licensing company,
Gyros Protein Technologies introduces Gyrolab Generic Rodent ADA Kit Reagents to support preclinical immunogenicity assessment
Ready-to-use kit expands range of bioanalysis kits, and enables generic detection of immune complexes in rodent samples
Nuclera eProtein Discovery system installed at leading academic institutes
11 installs successfully completed Novel platform automates a
Bio-Rad launches three StarBright Red Dyes and expands range of antibody markers conjugated to StarBright Violet Dyes to enhance immunology research
Bio-Rad's Range of StarBright Dyes Conjugated to Highly Validated Antibodies Now Totals 32 Dyes, Providing Greater Choice and Flexibility for Conventional and Full-Spectrum Flow Cytometry in Immunology Research.<
PlaqueTec closes $8 million equity financing
The financing was led by Lord Moynihan of Chelsea alongside The Future Fund, with support from existing investors Funding will support ongoing BIOPATTERN trial and build BIOCARTA database to tr
Asimov achieves 10x improvement in lentiviral production, launches new stable cell line development service
Stable lentiviral (LV) cell line development service achieves unconcentrated titers >1E9 TU/mL for therapeutic transgenes.
Calluna Pharma appoints Margrethe Sørgaard as Senior Vice President of Clinical Operations and Pharmacovigilance
First senior executive appointment made following Company launch to oversee strategic development of clinical programs
Neurolentech signs technology access partnership with Kaerus Bioscience to advance neurodevelopmental disorder research
Kaerus Bioscience will access Neurolentech’s NDD Drug Discovery Platform to support development of its preclinical asset pipeline for numerous genetic syndromes.
Zyme Communications expands UK head office with new facilities at Cambridge Innovation Park
Investment in new headquarters forms part of ongoing company growth plans and supports Zyme’s continued success, following client base and team expansion.
Sphere Fluidics appoints Edward Rayner as Non-Executive Director
Ed Rayner joins Sphere Fluidics as new board member to strengthen the Company’s strategic vision and ambition for commercial growth.
Bio-Rad announces collaboration agreement with Oncocyte to commercialize transplant monitoring with Droplet Digital PCR
Collaboration Aims to Provide Researchers Cutting-Edge Tools to Enable Transformational Monitoring of Key Biomarkers in Solid Tissue Transplants
Metrion Biosciences enhances High Throughput Screening services with access to Enamine compound libraries
Access to compound collection enables greater flexibility and efficiencies in screening and target identification
Preci and Biopredic International partner for higher performance of suspended pooled hepatocytes with extended longevity and large-scale availability
License agreement extends access to culture-stable pooled hepatocyte cell models with increased longevity for use in DMPK and ADME studies